A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 2
Recruiting
200
2026-05
Industry sponsor intelligence
Shenzhen Salubris Pharmaceuticals Co., Ltd.Clinical Pipeline.
Lead-sponsor view of Shenzhen Salubris Pharmaceuticals Co., Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 4
- Recruiting
- 1
- Active
- 0
- Completed
- 2
- Results posted
- 0
- Avg enrollment
- 284
Pipeline overview
Programs by phase and activity.
Velocity
Shenzhen Salubris Pharmaceuticals Co., Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
4phase labels
Early Phase 10
Phase 11
Phase 21
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Teriparatide → | 3 | 1 | 1 | 1 | 0 | 1 |
| Bivalirudin → | 1 | 0 | 0 | 1 | 0 | 0 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 3
Completed
493
2025-06
Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Osteoporosis
Phase 1
Completed
64
2021-02
Search sponsor records
All Shenzhen Salubris Pharmaceuticals Co., Ltd. studies.
This page groups studies where Shenzhen Salubris Pharmaceuticals Co., Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
4 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07579936A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing RegimensMay 12, 2026NCT07028320To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture RiskJun 25, 2025NCT04747392Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese AdultsFeb 10, 2021NCT02897037Bivalirudin in Acute Myocardial InfarctionNov 28, 2016